#National Institutes of Health

The ACTIV-2 study aims to determine whether neutralizing antibodies reduce the duration of COVID-19 symptoms.

Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness.

Preliminary results suggest anti-COVID19 nanobodies may be effective at preventing and diagnosing infections.

Anthony Fauci, President-elect Joe Biden and senior legislators were vaccinated publicly to demonstrate their confidence in vaccine safety.

Among 64 pregnant women who tested positive for SARS-CoV-2, none of their newborns tested positive.

Two Phase III clinical trials are evaluating monoclonal antibodies for people hospitalized with moderate COVID-19.

The study will evaluate short- and long-term health outcomes of COVID-19, including multisystem inflammatory syndrome.

Study findings suggest therapeutic targets to investigate for preventing cancer relapse.

Immune cells called T cells helped prevent reinfection and may be especially important if antibody levels are low or decline over time.

The vaccine demonstrated 95% efficacy in an ongoing Phase III trial.

If passed, the law would boost liver disease research and create a national strategy to tackle non-alcoholic steatohepatitis.

Recovery and death rates were similar in people treated with the anti-malaria drug or a placebo.

A carbohydrate called heparan sulfate, found on cell surfaces, may help the new coronavirus infects cells.

The study asks whether certain approved therapies or late-stage investigational drugs show promise against COVID-19.

It’s part of a $234 million federal initiative to improve COVID-19 testing among vulnerable populations.

Moderna/NIH mRNA produces strong immune response in people older than 55.